Inspire Medical Systems (INSP) Projected to Post Quarterly Earnings on Monday

Inspire Medical Systems (NYSE:INSP) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Monday, May 5th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $194.89 million for the quarter.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, analysts expect Inspire Medical Systems to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Inspire Medical Systems Stock Up 0.5 %

Inspire Medical Systems stock opened at $158.97 on Monday. The firm has a fifty day simple moving average of $162.86 and a two-hundred day simple moving average of $181.08. Inspire Medical Systems has a twelve month low of $123.00 and a twelve month high of $257.40. The company has a market capitalization of $4.73 billion, a PE ratio of 91.89, a P/E/G ratio of 2.86 and a beta of 1.39.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Royal Bank of Canada reduced their price target on Inspire Medical Systems from $260.00 to $215.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 15th. Piper Sandler dropped their price target on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. KeyCorp decreased their price objective on shares of Inspire Medical Systems from $234.00 to $216.00 and set an “overweight” rating on the stock in a research report on Monday, April 21st. Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a report on Tuesday, February 11th. Finally, Wells Fargo & Company reduced their price target on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Inspire Medical Systems currently has a consensus rating of “Moderate Buy” and an average price target of $218.90.

Insider Buying and Selling at Inspire Medical Systems

In other news, insider Randy Ban sold 25,584 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares of the company’s stock, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.